* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5MP2 vs CASIF, OGEN, ELOX: Days Payable Comparison
For the Biotechnology subindustry, Biodexa Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodexa Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Biodexa Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biodexa Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodexa Pharmaceuticals (STU:5MP2) has a Days Payable of 61.67 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biodexa Pharmaceuticals and its competitors. This is 38% above median its historical median of 44.77. Over the past decade, Biodexa Pharmaceuticals' Days Payable has ranged from 29.15 to 154.43. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #420 out of 708 companies in the Biotechnology industry, placing it in the top 59.3%.
Is Biodexa Pharmaceuticals' Days Payable too high?
Biodexa Pharmaceuticals' current Days Payable of 61.67 is 38% above median its 10-year median of 44.77. Over the past 10 years, this metric has ranged from a low of 29.15 to a high of 154.43. The Biotechnology industry median Days Payable is 113.56. Biodexa Pharmaceuticals' value of 61.67 is 45.7% below this industry median. Based on the distribution chart, Biodexa Pharmaceuticals ranks #420 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Days Payable compare to CASIF and OGEN?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #420 out of 708 companies for Days Payable. This places Biodexa Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Biodexa Pharmaceuticals' value of 61.67 is 45.7% below this benchmark. Historically, Biodexa Pharmaceuticals' own Days Payable has ranged from 29.15 to 154.43 over the past decade. While the company's 10-year median is 44.77 vs. the industry median of 113.56, Biodexa Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biodexa Pharmaceuticals's current Days Payable of 61.67 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biodexa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current Days Payable is 61.67, which is 38% above median its own 10-year median of 44.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Days Payable of 61.67. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Days Payable is 61.67, which is 38% above median its 10-year median of 44.77 and 45.7% below the Biotechnology industry median of 113.56. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Days Payable is 61.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued.
The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.
Key valuation signals for STU:5MP2:
Days Payable: 61.67 (38% above median its 10-year median of 44.77)
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
Industry Position: 45.7% below the Biotechnology median (#420 of 708)
No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score
Get the complete analysis for STU:5MP2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5MP2 has been successfully added to your 
